|1.60||-0.0300||-1.84%||Vol 304.61K||1Y Perf -80.64%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||0.04 2.48%|
|Target Price||24.73||Analyst Rating||Moderate Buy 2.09|
|Potential %||1.45K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/-94||Value Ranking||★★★★ 55.40|
|Insiders Value % 3/6/12 mo.||-/100/-98||Growth Ranking||★★★★+ 62.79|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/-91||Income Ranking||— -|
|Price Range Ratio 52W %||4.52||Earnings Rating||—|
|Market Cap||78.85M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.65|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||195.56K|
|Avg. Monthly Volume||349.97K|
|Avg. Quarterly Volume||439.57K|
C4 Therapeutics Inc. (NASDAQ: CCCC) stock closed at 1.63 per share at the end of the most recent trading day (a 7.95% change compared to the prior day closing price) with a volume of 347.97K shares and market capitalization of 78.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 99 people. C4 Therapeutics Inc. CEO is Andrew Hirsch.
The one-year performance of C4 Therapeutics Inc. stock is -80.64%, while year-to-date (YTD) performance is -72.37%. CCCC stock has a five-year performance of %. Its 52-week range is between 1.23 and 9.41, which gives CCCC stock a 52-week price range ratio of 4.52%
C4 Therapeutics Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.03, a price-to-sale (PS) ratio of 12.39, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -22.00%, a ROC of -25.73% and a ROE of -29.75%. The company’s profit margin is -%, its EBITDA margin is -213.20%, and its revenue ttm is $28.24 Million , which makes it $0.58 revenue per share.
Of the last four earnings reports from C4 Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. C4 Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for C4 Therapeutics Inc. is Moderate Buy (2.09), with a target price of $24.73, which is +1 445.62% compared to the current price. The earnings rating for C4 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
C4 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
C4 Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.54, ATR14 : 0.17, CCI20 : -12.24, Chaikin Money Flow : -0.06, MACD : -0.06, Money Flow Index : 51.38, ROC : -5.23, RSI : 48.45, STOCH (14,3) : 32.20, STOCH RSI : 1.00, UO : 40.44, Williams %R : -67.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of C4 Therapeutics Inc. in the last 12-months were: Adam Crystal (Option Excercise at a value of $0), Adam S. .Crystal (Sold 0 shares of value $0 ), Andrew J. Hirsch (Option Excercise at a value of $0), Fisher Stewart (Option Excercise at a value of $0), Hirsch Andrew (Option Excercise at a value of $0), Jolie Siegel (Option Excercise at a value of $0), Kelly Schick (Option Excercise at a value of $0), Kenneth Anderson (Sold 0 shares of value $-2 777 ), Kenneth C. Anderson (Option Excercise at a value of $2 777), Koppikar Utpal (Buy at a value of $31 735), Lauren White (Option Excercise at a value of $0), Scott N. Boyle (Option Excercise at a value of $0), Siegel Jolie (Option Excercise at a value of $0), Stewart Fisher (Option Excercise at a value of $0), Utpal Koppikar (Buy at a value of $31 735), White Lauren (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.